Form 4: SAB Biotherapeutics Chief Medical Officer Reports Stock Transaction

Alexandra Kropotova, Chief Medical Officer of SAB Biotherapeutics, reports the withholding of 1,179 common stock shares to cover tax obligations related to vesting restricted stock units.

Summary

• Alexandra Kropotova, the Chief Medical Officer of SAB Biotherapeutics, filed a Form 4 on April 1, 2025, reporting a transaction involving the company's common stock.
• On March 27, 2025, 1,179 shares of common stock were withheld to satisfy tax obligations related to the vesting of restricted stock units (RSUs).
• Following the transaction, Kropotova directly owns 47,249 shares of common stock, which includes 24,128 shares and 23,121 shares subject to vesting of RSUs granted under the company's 2021 Equity Incentive Plan.
• Each RSU represents a contingent right to receive one share of common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock transactions, indicating a neutral sentiment.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with SEC regulations.

Stakeholder Impact

• The transaction has a minimal impact on stakeholders as it is a routine tax-related stock withholding.

Key Dates

Keywords

Form 4, SAB Biotherapeutics, Stock Transaction, Alexandra Kropotova, Chief Medical Officer, Common Stock, Restricted Stock Units, RSUs, Equity Incentive Plan, Tax Withholding